Vascular disease is the leading cause of morbidity and mortality in the United States. There is a public health need for increased transfer of knowledge between the various disciplines that constitute this research field, and accelerated application of the basic information to clinical practice. The Stanford program addresses with a multidisciplinary program and faculty performing scientific and clinical work related directly to Vascular Medicine including cardiovascular and pulmonary medicine, endocrinology, hematology, nephrology, immunology, epidemiology and clinical trials design, cell and molecular biology, developmental and stem cell biology, tissue and mechanical engineering, physics and computational modeling, genetics/genomics,proteomics, physiology and molecular pharmacology. This proposal is designed to address the educational and clinical needs in the emerging specialty of Vascular Medicine. The program will produce clinician investigators with a deep fund of knowledge regarding vascular medicine, and a high level of proficiency in clinical research. This new breed of investigators will apply cutting edge technology to clinically relevant questions in vascular medicine, and they will be able to train the next generation of vascular internists.
Our Specific aims are to: 1) Develop, institute and annually evaluate a one year core clinical training program that confers competency in the management of arterial, venous and lymphatic diseases and associated disorders;2) Formulate, initiate and annually update a didactic training program in clinical research emphasizing clinical trial design, biostatistics and bioinformatics, genomics and proteomics, regulatory affairs, and responsible conduct of research;3) Provide a clinical research experience guided by an experienced Mentor, facilitated by a cohort of collaborative Co-mentors, and focused on a clinical research project. Other elements include exposure to trial design, interaction with and direct participation on the Institutional Review Board, database management and analysis, manuscript preparation, and grant writing. Lay description: Diseases of the arteries and veins cause most of the hospitalizations and deaths in the United States. Stanford University proposes a comprehensive educational program that will train a new breed of doctors that can recognize and treat these diseases, develop new therapies, and train young doctors in the care of people with vessel disease. (End of Abstract).
|Corey, Daniel M; Rosental, Benyamin; Kowarsky, Mark et al. (2016) Developmental cell death programs license cytotoxic cells to eliminate histocompatible partners. Proc Natl Acad Sci U S A 113:6520-5|
|Corey, Daniel M; Rinkevich, Yuval; Weissman, Irving L (2016) Dynamic Patterns of Clonal Evolution in Tumor Vasculature Underlie Alterations in Lymphocyte-Endothelial Recognition to Foster Tumor Immune Escape. Cancer Res 76:1348-53|
|Sukhovershin, Roman A; Ghebremariam, Yohannes T; Cooke, John P (2015) Lansoprazole worsens asthma control in poor metabolizers: is nitric oxide involved? Ann Am Thorac Soc 12:1109-10|
|Chang, Peter; Nead, Kevin T; Olin, Jeffrey W et al. (2015) Effect of physical activity assessment on prognostication for peripheral artery disease and mortality. Mayo Clin Proc 90:339-45|
|Ghebremariam, Yohannes T; Erlanson, Daniel A; Cooke, John P (2014) A novel and potent inhibitor of dimethylarginine dimethylaminohydrolase: a modulator of cardiovascular nitric oxide. J Pharmacol Exp Ther 348:69-76|
|Ghebremariam, Yohannes T; Huang, Ngan F; Kambhampati, Swetha et al. (2014) Characterization of a fluorescent probe for imaging nitric oxide. J Vasc Res 51:68-79|
|Priest, James R; Nead, Kevin T; Wehner, Mackenzie R et al. (2014) Self-reported history of childhood smoking is associated with an increased risk for peripheral arterial disease independent of lifetime smoking burden. PLoS One 9:e88972|
|Ghebremariam, Yohannes T; Lee, Jerry C; LePendu, Paea et al. (2014) Response to letters regarding article, ""unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine"". Circulation 129:e428|
|Dunn, Louise L; Simpson, Philippa J L; Prosser, Hamish C et al. (2014) A critical role for thioredoxin-interacting protein in diabetes-related impairment of angiogenesis. Diabetes 63:675-87|
|Botham, Crystal M; Bennett, William L; Cooke, John P (2013) Clinical trials of adult stem cell therapy for peripheral artery disease. Methodist Debakey Cardiovasc J 9:201-5|
Showing the most recent 10 out of 58 publications